BioRestorative Therapies (BRTX) & Its Rivals Financial Contrast

BioRestorative Therapies (OTCMKTS:BRTX) is one of 442 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare BioRestorative Therapies to related companies based on the strength of its institutional ownership, earnings, valuation, analyst recommendations, profitability, dividends and risk.

Profitability

This table compares BioRestorative Therapies and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioRestorative Therapies	-13,728.83%	-120.47%	-114.48%
BioRestorative Therapies Competitors	-8,545.43%	-125.62%	-26.85%

Analyst Ratings

This is a summary of current ratings and recommmendations for BioRestorative Therapies and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioRestorative Therapies	0	0	1	0	3.00
BioRestorative Therapies Competitors	614	2093	5077	52	2.58

BioRestorative Therapies currently has a consensus price target of $15.00, suggesting a potential upside of 1,036.36%. As a group, “Biotechnology” companies have a potential upside of 90.90%. Given BioRestorative Therapies’ stronger consensus rating and higher possible upside, research analysts plainly believe BioRestorative Therapies is more favorable than its rivals.

Insider & Institutional Ownership

69.4% of BioRestorative Therapies shares are held by institutional investors. Comparatively, 32.7% of shares of all “Biotechnology” companies are held by institutional investors. 21.6% of BioRestorative Therapies shares are held by insiders. Comparatively, 22.5% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares BioRestorative Therapies and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioRestorative Therapies	$145,800.00	-$18.50 million	-0.38
BioRestorative Therapies Competitors	$141.52 million	-$21.56 million	64.83

BioRestorative Therapies’ rivals have higher revenue, but lower earnings than BioRestorative Therapies. BioRestorative Therapies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

BioRestorative Therapies has a beta of 61.51, meaning that its stock price is 6,051% more volatile than the S&P 500. Comparatively, BioRestorative Therapies’ rivals have a beta of 1.25, meaning that their average stock price is 25% more volatile than the S&P 500.

Summary

BioRestorative Therapies beats its rivals on 7 of the 13 factors compared.

About BioRestorative Therapies

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.